COX-2

Enzyme inhibitors may prevent recurrent gastric cancer

Published in Cancer Weekly, August 6th, 2002

by Sonia Nichols, senior medical writer - COX-2 inhibitors could be important for preventing recurrent or remnant gastric cancers, researchers say.

The cyclooxygenase (COX)-2 enzyme has been indicted in breast, pancreas, lung, and colon cancer formation, and has been linked to tumor angiogenesis, or neovascularization in some cancers. Medical researchers in Japan have reported that elevated levels of COX-2 can be found in tissues remaining after gastric cancer resection, signaling a role for COX-2 inhibitors in stopping the development of remnant gastric cancers.

"It is well known that the gastric remnant is at greater risk for the development of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-08-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry